FLUCELVAX QUADRIVALENT

This brand name is authorized in Canada, United States

Active ingredients

The drug FLUCELVAX QUADRIVALENT contains a combination of these active pharmaceutical ingredients (APIs):

1 Influenza, inactivated, surface antigen UNII EZQ32TF2AS - INFLUENZA A VIRUS A/NEBRASKA/14/2019 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)

Read about Influenza, inactivated, surface antigen

2 Influenza, inactivated, surface antigen UNII 5MIR93VLG8 - INFLUENZA A VIRUS A/DELAWARE/39/2019 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)

Read about Influenza, inactivated, surface antigen

3 Influenza, inactivated, surface antigen UNII G4VX46P9M6 - INFLUENZA B VIRUS B/SINGAPORE/INFTT-16-0610/2016 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)

Read about Influenza, inactivated, surface antigen

4 Influenza, inactivated, surface antigen UNII ZBC2SPA9BZ - INFLUENZA B VIRUS B/DARWIN/7/2019 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)

Read about Influenza, inactivated, surface antigen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BB02	Influenza, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BB Influenza vaccines
Discover more medicines within J07BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02494248
Country: US	FDA, National Drug Code	Identifier(s): 70461-320, 70461-420